Background & Aims: In chronic hepatitis C, interferon
Factors that have been frequently demonstrated to inalfa induces sustained remission in less than 30% of fluence the outcome of the therapy include age and duratreated patients. The aim of this study is to analyze tion of infection, 7-9 absence of cirrhosis, 10-12 body viral status early after initiation interferon therapy as a weight, 12 g-glutamyl transpeptidase (GGTP) levels, 12 vipredictor of treatment outcome. Methods: One hundred ral genotype, [13] [14] [15] [16] [17] [18] [19] [20] and pretreatment serum titer of HCV eighty-one patients with chronic hepatitis C who had RNA. 13,16 -22 However, pretreatment variables have not been treated with interferon alfa for 12 months (median been useful to date in predicting the response to treatfollow-up, 49 months) were studied. Viremia and aminoment in individual cases. 23 Thus, to find more reliable transferase levels at the first and third months of parameters that might be useful in anticipating the retherapy as well as 10 pretreatment variables were sults of the treatment, we have evaluated the predictive assessed as potential independent predictors of susvalue of the elimination of viremia at 1 month into tained response to treatment. Results: Sustained retreatment in a large cohort of patients with chronic hepasponse occurred in 51 patients (28%). At month 1 of treatment, viral persistence accurately predicted nontitis C followed up for more than 4 years. We have found response (predictive value, 95.3; 95% confidence interthat tracking the evolution of viremia early after starting val, 86.0-98.8; P õ 0.0001). Independent predictors IFN therapy is the best predictive factor for long-term of sustained response were undetectable viremia at outcome from this therapy. This parameter and patient the first month of therapy (P õ 0.001), undetectable age were used to build a logistic model to estimate the viremia at the third month (P õ 0.001), younger age adjusted odds ratios (ORs) of a sustained response (SR) (P Å 0.006), nonsporadic infection (P Å 0.012), and to IFN treatment.
higher pretreatment aspartate aminotransferase levels (P Å 0.032). In patients who cleared HCV RNA at month
Patients and Methods
1 of therapy, the predicted probability of sustained reOne hundred eighty-one patients in whom chronic sponse averaged 70% for those younger than 30 years hepatitis C had been diagnosed were included in the study. and diminished by 10% for each decade of age. ConcluAll patients had undergone a 1-year course of IFN-a treatment sions: Failure to clear HCV RNA at month 1 of treatment in our center between 1988 and 1993. Before starting treatis strongly and independently associated with a very ment, they had shown persistent (ú6-month) elevation of alalow probability of a sustained response to interferon.
nine aminotransferase (ALT) concentrations 1. ally presented SR and those who did not, 16 variables were analyzed: age, sex, body mass index (weight in kilograms ditreatment and during the follow-up period was also required vided by squared height in meters), source of infection (spofor inclusion. Patients were instructed to stop alcohol intake radic/nonsporadic), pretreatment ALT, aspartate aminotransat least 6 months before starting treatment.
ferase (AST), and GGTP values, existence of cirrhosis, viral IFN (3 MU) was administered daily for 2, 3, or 4 months genotype, pretreatment viral load, type and total dose of IFN (to 128, 25, and 28 patients, respectively) and then three times used, and serum HCV RNA and ALT levels at the end of the a week (1.5-3 MU) for the following months until 1 year of first and third months of treatment. Predictive values for SR therapy was completed in all cases. Table 1 shows the clinical, or no response to IFN were calculated for HCV RNA test biochemical, histological, and virological characteristics of the results and normal or raised ALT at the end of the first and patients.
third months of treatment.
The multivariable model (model A) was performed using
Follow-up During and After Therapy
the BMDP LR Dynamic software, and variables were selected using the purposeful method. 27 Initial candidate variables were The median follow-up after completion of the treatment for all the patients was 49 months (range, 18-84 those with a P value of õ0.25 in the univariate analysis. A second model (model B) was built with the same criteria. In months). During the period of treatment, patients were followed up monthly with serial determinations of ALT concenthis model we included only those patients (n Å 132) with an available serum HCV RNA determination at the end of tration. Serum HCV RNA was tested in all patients before the start of treatment and at the end of 12 months of IFN the first month of treatment. A third model was developed to assess the predictive value of two variables (age and HCV therapy. HCV RNA was also determined in 132 patients at 1 month and in 137 patients at 3 months of therapy (both were RNA at the first month), which, having highly significant associations with the therapeutic response in the previous analdetermined in 101 patients).
During follow-up, ALT concentrations were determined evyses, could be at the same time easily obtained in each patient. A receiver operating characteristic (ROC) plot was constructed ery 3-6 months. HCV RNA was tested 1 year after the end of IFN therapy and at the end of follow-up in all patients. A with every cutoff point of the predicted probabilities, and the area under the curve was measured to assess the degree of variable number of additional HCV RNA determinations (one / 5E22$$0020 10-07-97 22:34:25 gasas WBS-Gastro discrimination provided by the model. ROC Curve Analyzer At 1 month into treatment, 68 of 132 tested patients had cleared HCV RNA from serum. Among these 68 patients, 34 (50%) had SR and 34 (50%) were nonresource of infection, higher pretreatment levels of ALT, sponders. On the other hand, among the 64 subjects who lower pretreatment levels of GGTP, absence of cirrhosis, remained viremic at month 1 of therapy, 61 (95.3%) genotype 3, clearance of serum HCV RNA at the first were nonresponders, whereas only 3 (4.68%) had SR.
or third month of treatment, and (in a separate analysis Thus, only 3 of the 37 patients with SR who were anaof 74 patients in whom viral load was determined) lower lyzed had detectable HCV RNA in serum after the first pretreatment viral load (P Å 0.04). Two other variables month of treatment; 2 of them became negative in the showed only a borderline association in the univariate third month and 1 in the sixth month of therapy. There analysis: higher pretreatment levels of AST (P Å 0.06) was a significant difference between patients with SR and lower ALT values at month 3 of therapy (P Å 0.06). and nonresponders in the proportion of patients who had
We found no significant association between SR and sex, cleared HCV RNA after the first month: 34 of 37 pawhole IFN dose, type of IFN administered, or ALT values tients with SR (92%) and 34 of 95 nonresponders (36%; at month 1 of treatment (considered as a continuous P õ 0.001). At month 3 of therapy, 35 of 39 patients variable). with SR (89.7%) and 45 of 98 nonresponders (45.9%)
In the first multivariate logistic regression model were HCV RNA negative (P õ 0.001).
(model A), which did not include HCV RNA (Table 3) , Transaminase levels measured at the first and third five variables were shown to be significantly and indepenmonths after the start of therapy showed less significant dently associated with SR: younger age, nonsporadic association with the response. At 1 month into treatment, source of infection, genotype 3, higher baseline levels of 61 patients (34%) had normal ALT levels. Among these AST, and lower levels of GGTP. Cirrhosis showed a 61 patients, 25 (41%) were patients with SR and 36 borderline association (P Å 0.06) and was also included (59%) were nonresponders. Among the 120 subjects who in this model. continued to have abnormal ALT levels after month 1
In the second model (model B), involving 132 patients of therapy, 94 (78%) were nonresponders, whereas 26 with available determination of HCV RNA at the end (22%) had SR. There was a significant difference between of the first month of treatment (Table 3) , clearance of patients with SR and nonresponders in the proportion serum HCV RNA at month 1 into therapy was the of patients who had normalized ALT at the first month strongest independent predictor of an SR. Table 2 .
In a separate multivariable analysis of 74 patients in whom viral load was quantitated, a lower pretreatment The univariate analysis of the clinical and virological characteristics showed the following variables to be sigviral load also behaved as an independent predictor of an SR (P Å 0.03; results not shown). nificantly associated with a higher probability of SR (Table 3): younger age, lower body mass index, nonsporadic HCV RNA was studied at the end of the third month / 5E22$$0020 10-07-97 22:34:25 gasas WBS-Gastro Viremia at the third month was analyzed in 137 patients, of whom 101 had also HCV RNA determinations done at first month. When these 101 cases were included in a multivariate analysis it was found that the magnitude of association with sustained response was similar to that of first-month HCV RNA clearance (P õ 0.001).
of treatment in 137 patients, 101 of whom also under-2.67; df, 8; P Å 0.96). The area under the ROC curve was 0.833 (95% CI, 0.762-0.965; Figure 1) , showing went HCV RNA determination at the end of the first month. When viremia at month 1 and at month 3 were acceptable discriminating capabilities of the model. Accordingly, the information provided by the two variables included in a multivariate analysis comprising these 101 patients (Table 3) , we found that the magnitude of associwould allow a correct classification of nearly 85% of the patients as patients with SR or nonresponders. ation with SR was similar for the two variables. Younger age, nonsporadic source of infection, and higher levels of We calculated the absolute predicted probabilities of an SR for each combination of age and the serum HCV AST retained their independent association with SR.
A model to assess the predictive value of the joint RNA status at the end of the first month of treatment. For a patient with negative viremia at the end of the function of age and clearance of viremia at the end of the first month of treatment was developed with the 132 first month of treatment, the predicted probability of long-term response averaged 50%, with wide variability patients with available first-month viremia (mean age, 44.5; SD, 14.06; positive viremia at first month of treatdepending on age. The predicted probability reached 70% for a patient younger than 30 years old and diminment, n Å 64; negative viremia at first month of treatment, n Å 68 16, 19, 30 have shown that HCV RNA disappears promptly from serum (by the fourth week) in some of the patients undergoing the therapy. Orito et al. 19 suggested that early HCV RNA clearance might be associated with long-term response to IFN. In these studies, however, the number of patients was limited, the followup was restricted to 6 months, and the criteria for SR were based solely on biochemical data. 16, 19 In the present study, involving patients followed up for more than 4 years, we found that disappearance of serum HCV RNA early after starting IFN was the best predictor of an SR as defined by both biochemical and virological data. However, the predictive value for an SR of HCV RNA clearance at month 1 of therapy averages only 50%, with clearance, persistence of HCV RNA in serum at 1 month of treatment accurately predicted nonresponse (predictive value, 95.3%). ure 2). On the other hand, if the viremia persisted posiViral status at the end of the third month of therapy tive after 1 month of treatment, the predicted probability showed the same predictive value for SR and for no SR of long-term response was very low (4.7%; Figure 2 ).
as the viremia at the end of the first month. These data Discussion indicate that predictions on treatment outcome based on viremia can be done as early as at the first month of In our series of patients, pretreatment variables therapy without risking accuracy. Thus, the present work independently associated with a higher probability of SR provides evidence to support the importance of early to IFN were younger age, nonsporadic source of infection, determination of viremia during therapy and offers a higher AST levels, lower GGTP values, low viral load, reliable marker of nonresponse (persisting viremia after HCV genotype 3, and absence of cirrhosis (the latter 1 month of treatment), which can be useful clinically. with borderline association). All these variables, except
Clearance of HCV RNA preceded normalization of AST values, have been previously reported to be associserum transaminase levels. Compared with HCV RNA ated with long-term response. 8,9,12 -14,16,19,20,22,28 Among clearance, normalization of ALT at month 1 or at month all the pretreatment parameters, age was found to be an 3 of therapy was found to be a poor predictor of the important predictor. Duration of the disease could not be determined in a study like ours with a high percentage of sporadic cases. Although age could be a surrogate for duration of the disease, other studies 8 have shown that younger age and shorter duration of the hepatitis were independently associated with SR to IFN. The importance of aging in the evolution of chronic hepatitis C has been highlighted by a recent study involving a great number of patients. 29 It seems possible that weaker defense mechanisms against HCV determine poorer response to IFN with advancing age.
Although pretreatment variables could be useful to predict response to IFN in groups of patients, these data are of little help in isolated cases. 23 To find more reliable status at month 1 of therapy was the main independent / 5E22$$0020 10-07-97 22:34:25 gasas WBS-Gastro response to IFN (Table 2 ). Only after 6 months of treataverages 50%, varying from 70% to 20% depending on age. Although the validation of the model combining ment had transaminases acquired a statistically significant association with SR (predictive values, 45.8% for age and early virological response ( Figure 2 ) needs confirmatory studies using external data and larger sample SR and 82.4% for no response; data not shown).
size, we can suggest the following recommendation: IFN From our findings and other reports, it seems that IFN may be given to any patient with diagnosis of chronic exerts its antiviral activities very shortly after initiation of hepatitis C, independent of his/her age, histological acthe treatment. Thus, Chayama et al. 31 reported 63% tivity, genotype, or viral load. After 1 month of daily IFN HCV RNA clearance after 2 weeks of 6 MU of daily IFN administration, withdrawal of treatment or combination treatment. On the other hand, Zeuzem et al. 32 showed a therapy should be considered in those patients who have high turnover for HCV, with a half-life of Ç2 days. It not cleared HCV RNA. In this way, we can avoid unnecis then conceivable that monitoring of serum HCV RNA essarily prolonging the administration of IFN without during a period of time even shorter than 1 month could excluding those cases who would otherwise experience a also be of value in predicting the response to IFN. Besustained response to the therapy. In selected patients, cause there is a strong association between prompt elimiother treatment benefits (e.g., slower progression to cirnation of viremia and response to IFN, it could be specurhosis, decreased risk of hepatocellular carcinoma) should lated that the best approach to eradicate HCV infection also be taken into account before discontinuation of IFN. would be to attempt to rapidly reduce viral load by using higher doses of antiviral agents early at the beginning mination of serum HCV RNA after receiving IFN for 1
Interrelationship of blood transfusion, non-A, non-B hepatitis and month was developed because these two variables are change from one determination to another and therefore 7. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, do not seem very useful for prognostic assessments. and adverse effects of the treatment.
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In summary, the main finding of the present study is becomes negative the probability of sustained response / 5E22$$0020 10-07-97 22:34:25 gasas WBS-Gastro
